Anticipated $-0.14 EPS for Moleculin Biotech, Inc. (MBRX) as of May, 21

Modesto Morganelli
Mag 17, 2018

More recent Moleculin Biotech, Inc. (NASDAQ:MBRX) news were announced by Streetinsider.com, Globenewswire.com and Nasdaq.com.

According to Zacks, "Moleculin Biotech, Inc.is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates". The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.06, Bloomberg Earnings reports. The company's stock had a trading volume of 260 shares, compared to its average volume of 765,949.

Separately, ValuEngine upgraded Moleculin Biotech from a strong sell rating to a sell rating in a research note on Friday, February 2nd.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings results on Tuesday, May 15th. MBRX touched $1.7252 during the last trading session after $0.0148 change.Currently Moleculin Biotech, Inc.is uptrending after 70.64% change in last May 16, 2017. Moleculin Biotech has a 12-month low of $1.74 and a 12-month high of $1.74. The company has a market cap of $44.84 million, a price-to-earnings ratio of -3.70 and a beta of -0.88. The Company's lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia.now it has negative earnings. The firm also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The first one has "Moleculin Biotech (MBRX) Enters Pact with BSP Pharmaceuticals for its Leukemia Drug Candidate" as a title and was announced on April 24, 2018.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE